Clinical trials: Acute Myeloid Leukemia in Children, active
Acute Leukemia, Acute Lymphoblastic Leukemia, Pediatric
Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia
The survival of children, adolescents and young adults (AYA) with acute leukemia has improved dramatically over the last two decades.
- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia, Pediatric, Acute Myeloid Leukemia in Children, Myeloproliferative Neoplasm
- Trial name
- NCT06421155
- Testing
- MRF with neurocognative studies
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Case Comprehensive Cancer Center
Leukemia, Acute Myeloid Leukemia
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
This is a single-arm pilot clinical trial evaluating dalbavancin-based prophylaxis in children and adolescents with acute myeloid leukemia or relapsed lymphoblastic leukemia receiving myelosuppressive chemotherapy.
- Conditions
- Leukemia, Acute Myeloid Leukemia, Lymphoblastic Leukemia in Children
- Trial name
- NCT06810583
- Testing
- Dalbavancin, Fluoroquinolone (either ciprofloxacin or levofloxacin at the discretion of the treating clinician)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Lymphoid Leukemia, Acute Myeloid Leukemia in Children
Study of the Medullary Microenvironment in Acute Childhood Leukemia
Acute leukemia (AL) is the most common cancer in children. Despite the optimization of chemotherapy treatments and the development of supportive care, a certain number of LAs relapse and/or progress to death of the child.
- Trial name
- MILA (NCT05792007)
- Testing
- Biological sampling in patients, Biological sampling in control patients
- Where
- 3 sites in France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Acute Myeloid Leukemia in Children
CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients
The CHIP-AML22 Master protocol has the overall aim of increasing the cure rate in newly diagnosed pediatric de novo AML patients, while avoiding unnecessary toxicity.
- Trial name
- NCT05994690
- Testing
- Standard Intervention Rc, Investigational Intervention Rc, Standard Intervention Ri
- Where
- Netherlands
- Volunteers
- 905 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Acute Myeloid Leukemia in Children
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
The CHIP-AML22 Master protocol has the overall aim of increasing the cure rate in newly diagnosed pediatric de novo AML patients, while avoiding unnecessary toxicity.
- Trial name
- CHIP-AML22/Q (NCT06262438)
- Testing
- Quizartinib, Etoposide, Dexrazoxane
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
This study will evaluate pediatric patients with malignant or non-malignant blood cell disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa and beta cells that comes from a partially…
- Conditions
- Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
- Trial name
- NCT03301168
- Testing
- BPX-501 T cells, Rimiducid
- Where
- 10 sites in United States
- Volunteers
- 120 people
- Sponsor
- Bellicum Pharmaceuticals